| Deniece Nicole Johnson, MD | |
|
550 Peachtree St Ne, Emory University Hospital Midtown, Atlanta, GA 30308-2208 | |
| (404) 778-1000 | |
| Not Available |
| Full Name | Deniece Nicole Johnson |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 12 Years |
| Location | 550 Peachtree St Ne, Atlanta, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306102298 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 073623 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emory University Hospital Midtown | Atlanta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Emory Clinic, Inc | 8820901408 | 2687 |
News Archive
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk of death.
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke - and thus the cells' likelihood of suffering permanent damage.
› Verified 4 days ago
| Entity Name | The Emory Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396798229 PECOS PAC ID: 8820901408 Enrollment ID: O20031110000503 |
News Archive
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk of death.
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke - and thus the cells' likelihood of suffering permanent damage.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Deniece Nicole Johnson, MD 550 Peachtree St Ne, Emory University Hospital Midtown, Atlanta, GA 30308-2208 Ph: () - | Deniece Nicole Johnson, MD 550 Peachtree St Ne, Emory University Hospital Midtown, Atlanta, GA 30308-2208 Ph: (404) 778-1000 |
News Archive
Andrea Morelli, M.D., of the University of Rome, Italy, and colleagues conducted a study to investigate the effect of the short-acting beta-blocker esmolol on the heart rate of patients with severe septic shock and high risk of death.
A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.
ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.
Therakos, Inc., a pioneer in the innovative treatment of extracorporeal photopheresis (ECP) for immune modulation therapy, today announced that the first patient has been enrolled in its Phase IIb clinical study evaluating the use of the company's photopheresis technology in the treatment of patients with moderate-to-severe chronic Graft-versus-Host Disease (GvHD).
A small molecule known to regulate white blood cells has a surprising second role in protecting brain cells from the deleterious effects of stroke, Johns Hopkins researchers report. The molecule, microRNA-223, affects how cells respond to the temporary loss of blood supply brought on by stroke - and thus the cells' likelihood of suffering permanent damage.
› Verified 4 days ago
Dr. Tianna E. Johnson, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw, Suite 635, Atlanta, GA 30309 Phone: 404-367-3014 Fax: 404-367-3558 | |
Dr. Maha Osman Sulieman, MBBS Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1364 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-712-2000 | |
Sarah Latif, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw Ste 635, Atlanta, GA 30309 Phone: 404-367-3014 | |
Dr. Tait Thomas Jones, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1362 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-727-5658 | |
Candice Marie Delk, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 35 Collier Rd Nw, Suite 635, Atlanta, GA 30309 Phone: 404-367-3014 Fax: 404-367-3558 | |
Thara Mrithula Vidyasagaran, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1364 Clifton Rd Ne, Atlanta, GA 30322 Phone: 404-712-7100 | |
Matthew Jason Brown, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 49 Jesse Hill Jr Dr Se, Atlanta, GA 30303 Phone: 404-778-7777 |